News | February 25, 2025
Teva and Sanofi present new outcome from Phase 2b study of duvakitug
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
the inspection conducted from January 27 to January 31, 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
The Alathur facility specializes in the production of Cephalosporin antibiotics
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Subscribe To Our Newsletter & Stay Updated
